May 15 (Reuters) - Bayer AG:
* US FDA approves Bayer Pharmaceuticals' Xofigo for advanced prostate cancer
* FDA approves Bayer's Xofigo to treat men with late-stage
castration-resistant prostate cancer that has spread to bones but not other
* FDA approves Bayer's Xofigo was being approved more than 3 months
ahead of its review date of August 14
* Source text for Eikon * Further company coverage
(Bangalore Newsroom; +1 646 223 8780)
Copyright Thomson Reuters 2013. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.